Editor Profile

Mark V. Dahl, MD

Associate Editor

About the NEJM Journal Watch Dermatology Board

Mark V. Dahl, MD, is currently Professor of Dermatology, College of Medicine, Mayo Clinic, and Senior Consultant in the Department of Dermatology at Mayo Clinic in Scottsdale/Phoenix, Arizona. He has served as President of the American Academy of Dermatology and as Vice President of the Society for Investigative Dermatology. He is the founder of Camp Discovery, a camping program for children with severe skin diseases. Dr. Dahl is a recipient of the Gold Medal, the American Academy of Dermatology's highest honor, and was named a Master Dermatologist by the organization in 2006. His research has focused on immunology, infections, and inflammatory diseases of the skin, including studies related to immunodeficiency, chemotaxis, granuloma annulare, immunofluorescence, bullous diseases, psoriasis, cutaneous irritation, allergy, rosacea, the epidermal acetylcholine network, and cutaneous fungal infections. Dr. Dahl joined the NEJM Journal Watch Dermatology board in 2007.

Disclosures

Consultant / Advisory board

Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics

Equity

Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards

UpToDate

Leadership positions in professional societies

National Rosacea Society (Chairman, Medical Board)

Summaries by Mark Dahl

  • August 6, 2015

    Dapsone Gel for Papulopustular Rosacea

    1. Mark V. Dahl, MD

    Scores and symptoms were similar in a comparison of dapsone gel and metronidazole.

  • July 24, 2015

    Metformin: A New Approach to Acne Therapy?Free

    1. Mark V. Dahl, MD

    The use of metformin and a hypocaloric diet significantly improved stubborn acne in young men with an altered metabolic profile.

  • July 24, 2015

    Stem Cells and Wounds

    1. Mark V. Dahl, MD

    Stem cell therapies are exciting to contemplate, but the potential benefits have yet to be confirmed.

  • June 30, 2015

    Heartthrobs and RosaceaFree

    1. Mark V. Dahl, MD

    A Taiwanese study showed higher prevalences of hypertension, dyslipidemia, cardiovascular disease, peripheral artery occlusive disease, and cerebral infarction in rosacea patients.

  • June 26, 2015

    Headstrong Seborrheic Dermatitis

    1. Mark V. Dahl, MD

    Pulsed doses of systemic itraconazole (200 mg/day for two consecutive days each month) effectively treat moderate-to-severe seborrheic dermatitis and maintain remissions.

  • June 17, 2015

    Lymphomatoid Papulosis and Low-Dose Methotrexate

    1. Mark V. Dahl, MD

    Although most patients with LyP don't need systemic treatment, methotrexate is generally effective and safe for those who do.

Pages